Control
Sep 12 2024 |
et al., BMC Infectious Diseases, doi:10.1186/s12879-024-09886-w | Nebulized inhalation of plasma-activated water in the treatment of progressive moderate COVID-19 patients with antiviral treatment failure: a randomized controlled pilot trial |
| 9% higher progression (p=1), 73% greater improvement (p=0.04), 28% shorter hospitalization (p=0.16), and 30% higher hospital discharge (p=0.24). RCT 23 moderate COVID-19 patients with antiviral treatment failure, showing nebulized plasma-activated water (PAW) improved chest CT and accelerated cough resolution compared to saline control, however there was no significant difference .. | ||